Equities Analysts Offer Predictions for IDEXX Laboratories, Inc.’s Q1 2026 Earnings (NASDAQ:IDXX)

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Analysts at William Blair issued their Q1 2026 EPS estimates for IDEXX Laboratories in a research note issued to investors on Monday, October 7th. William Blair analyst R. Daniels anticipates that the company will post earnings per share of $3.55 for the quarter. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $10.45 per share. William Blair also issued estimates for IDEXX Laboratories’ Q3 2026 earnings at $3.51 EPS and FY2026 earnings at $14.14 EPS.

Several other research firms also recently weighed in on IDXX. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Finally, Piper Sandler decreased their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $581.00.

IDEXX Laboratories Stock Down 0.3 %

NASDAQ IDXX opened at $473.28 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $487.94 and a two-hundred day moving average of $494.71. The firm has a market capitalization of $39.09 billion, a price-to-earnings ratio of 45.52, a PEG ratio of 4.32 and a beta of 1.33. IDEXX Laboratories has a 52 week low of $372.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter last year, the company earned $2.67 earnings per share. The company’s revenue for the quarter was up 6.4% on a year-over-year basis.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of IDXX. Crestmont Private Wealth LLC raised its position in IDEXX Laboratories by 14.4% in the 3rd quarter. Crestmont Private Wealth LLC now owns 525 shares of the company’s stock valued at $265,000 after purchasing an additional 66 shares in the last quarter. CHICAGO TRUST Co NA raised its position in shares of IDEXX Laboratories by 29.3% during the 3rd quarter. CHICAGO TRUST Co NA now owns 3,990 shares of the company’s stock worth $2,016,000 after acquiring an additional 904 shares in the last quarter. Carnegie Investment Counsel acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $205,000. Gateway Investment Advisers LLC raised its position in shares of IDEXX Laboratories by 1.2% during the 3rd quarter. Gateway Investment Advisers LLC now owns 11,075 shares of the company’s stock worth $5,595,000 after acquiring an additional 134 shares in the last quarter. Finally, Perfromance Wealth Partners LLC raised its position in shares of IDEXX Laboratories by 3.2% during the 3rd quarter. Perfromance Wealth Partners LLC now owns 3,526 shares of the company’s stock worth $1,781,000 after acquiring an additional 110 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.